Candidate drug modification variant Diabetes treatment drug development research has made important progress

Medicine Network December 31st reporter 30 from the Chinese Academy of Sciences Hefei Research Institute was informed that the hospital Wang Junfeng task force on the diabetes candidate drug FGF21 transformation to obtain new variants, diabetes mice experimental results, etc. show that it has excellent blood sugar lowering, weight loss effect and good drug."
research has applied for national invention patents and international patent protection, and has reached preliminary intention with a number of enterprises to jointly promote clinical trials and industrialization.
, diabetes ranks ninth among the world's top 10 causes of death in 2019, according to the World Health Organization's WHO.
, published this year in the British Medical Journal (BMJ), the world's leading medical journal, found that the number of people with diabetes in China has reached 130 million, the highest in the world.
At present, diabetes drug treatment to control blood sugar, delay the occurrence of related complications mainly, and can not completely cure diabetes, the main reason is that the most important reason is that the diabetes treatment drug action mechanism mostly revolves around insulin has the function of lowering blood sugar, but not for the real cause of diabetes - insulin resistance, cure the problem.
, the development of therapeutic drugs that improve insulin resistance will help to better treat diabetes.
FGF21 is an endocrine protein that regulates metabolism, has the advantages of improving the body's insulin resistance and promoting the energy metabolism of glycolipids, and has the potential to treat metabolic-related diseases such as obesity, diabetes and non-alcoholic fatty liver.
has made a series of progress in drug development based on FGF21, but it has not solved the problem of FGF21 pharmacological dynamics and stability, which requires frequent administration, which greatly hinders clinical application.
in this study, the researchers analyzed the solution structure of FGF21 by US MRI spectrometology, relying on the steady-state strong magnetic field experimental device, and finally modified a new variant FGF21SS.
showed good performance in protein stability experiments and diabetes trials in obese mice.
reported that the current industrialization process of the drug is steadily advancing, has reached an agreement with a number of companies to jointly carry out a series of preclinical trials, is expected to apply for clinical approval after 2 years to carry out clinical trials, is expected to be used in clinical conversion for diabetes, obesity and non-alcoholic fatty liver and other chronic metabolic diseases treatment.
the results were published in the European Molecular Biology Organization Report (EMBO reports), a leading international journal on molecular biology.
。